文献速递神经肌肉病

Verdiperstat治疗肌萎缩侧索硬化的随机HEALEY ALS平台试验结果

Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial.
PubMed 文献 · JAMA Neurol · 2025-02-17

该研究为多中心、双盲、随机平台试验,纳入167例ALS患者,按3:1随机接受口服verdiperstat 600mg每日两次或安慰剂治疗24周。主要终点为ALSFRS-R与生存联合模型疾病进展率比(DRR),估计DRR为0.98(95%可信区间0.77-1.24),verdiperstat较安慰剂估计减缓进展2%(95%可信区间-23%至24%),后验概率0.57。结论认为verdiperstat不太可能改变ALS疾病进展。

要点

  • verdiperstat 600mg每日两次治疗24周,估计DRR为0.98,后验概率0.57。
  • verdiperstat较安慰剂估计减缓进展2%,95%可信区间-23%至24%。
  • verdiperstat总体安全且耐受良好,常见不良事件为恶心、失眠和促甲状腺激素升高。

核心结论

  • 结果表明verdiperstat治疗不太可能改变ALS疾病进展。

研究设计与样本

  • HEALEY ALS平台试验为多中心、双盲、永续平台设计、随机临床试验,共享试验基础设施和安慰剂数据。
  • 研究于2020年7月至2022年4月在美国54个ALS转诊中心开展。
  • 纳入根据修订El Escorial标准诊断为临床可能、 probable、实验室支持 probable或 definite ALS的成人参与者。
  • 167例参与者随机接受verdiperstat(126例,75.4%)或方案特异性安慰剂(41例,25.6%),比例为3:1;另纳入其他方案同时随机分配的安慰剂组参与者进行分析。
  • verdiperstat组130例(78%)完成试验。

主要发现

  • 估计DRR为0.98(95%可信区间0.77-1.24;DRR<1的后验概率=0.57)。
  • verdiperstat较安慰剂估计减缓进展2%(95%可信区间-23%至24%;后验概率0.57)。
  • verdiperstat总体安全且耐受良好。
  • verdiperstat组常见不良事件为恶心、失眠和促甲状腺激素水平升高。

关键数值与推荐

  • 主要疗效终点为从基线至第24周疾病严重程度变化,采用ALSFRS-R与生存联合模型,以疾病进展率比(DRR)量化,DRR小于1表示verdiperstat相对安慰剂减缓疾病进展。

临床怎么用

  • 原文未报告临床实践建议。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Myeloperoxidase is one of the most abundant peroxidase enzymes in activated myeloid cells. Myeloperoxidase inhibitors may have a clinical benefit in amyotrophic lateral sclerosis (ALS) by slowing neurodegeneration via reduced neuroinflammation and oxidative stress. OBJECTIVE: To determine the safety, tolerability, and efficacy of verdiperstat, a selective myeloperoxidase inhibitor, in ALS. DESIGN SETTINGS AND PARTICIPANTS: Verdiperstat was tested as a regimen of the HEALEY ALS Platform Trial, a multicenter, double-blind, perpetual platform design, randomized clinical trial, with sharing of trial infrastructure and placebo data across multiple regimens. The study was conducted at 54 ALS referral centers across the US from July 2020 to April 2022. Adult participants with a diagnosis of clinically possible, probable, laboratory-supported probable, or definite ALS defined by the revised El Escorial criteria were randomized to verdiperstat or regimen-specific placebo. An additional group of participants concurrently randomized to placebo from other regimens was included in the analyses. INTERVENTIONS: Eligible participants were randomized in a 3:1 ratio to receive oral verdiperstat, 600 mg, twice daily or matching placebo for a planned placebo-controlled duration of 24 weeks. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was change from baseline through week 24 in disease severity, as measured by a joint model of ALS Functional Rating Scale-Revised and survival, with the treatment effect quantified by the disease rate ratio (DRR), with DRR less than 1 indicating a slowing in disease progression of verdiperstat relative to placebo. RESULTS: A total of 167 participants (mean [SD] age, 58.5 [11.4] years; 59 [35.3%] female; 108 [64.6%] male) were randomized to either verdiperstat (126 [75.4%]) or to placebo (41 [25.6%]). Among the participants randomized to the verdiperstat regimen, 130 (78%) completed the trial. The estimated DRR was 0.98 (95% credible interval, 0.77-1.24; posterior probability = 0.57 for slowing of disease progression [DRR <1]). Verdiperstat was estimated to slow progression by 2% vs placebo (95% credible interval, -23% to 24%; posterior probability 0.57). Verdiperstat was overall safe and well tolerated. Common adverse events in the verdiperstat group were nausea, insomnia, and elevated thyrotropin levels. CONCLUSIONS AND RELEVANCE: Results demonstrate that treatment with verdiperstat was unlikely to alter disease progression in ALS. TRIAL REGISTRATION: Clinical Trial Identifiers: NCT04297683 and NCT04436510.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Andrews J, Paganoni S, Macklin EA, et al. Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial. JAMA Neurol. 2025. PMID: 40067754. doi:10.1001/jamaneurol.2024.5249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。